AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$AXSM

Axsome Therapeutics, Inc.

Price · $AXSMvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $AXSM in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $AXSM in the last 30 days.

Top stories · $AXSMMore →
MAY 16·Simply Wall StreetMed

A Look At Axsome Therapeutics (AXSM) Valuation After AUVELITY Alzheimer’s Agitation Launch Plans And Earnings Update

Axsome Therapeutics (AXSM) is gaining attention after announcing plans to launch AUVELITY for Alzheimer’s disease agitation in June, supported by an expanded sales force and anticipated broad Medicare Part D coverage. The stock has seen significant momentum, including a 26.11% return over 30 days and 116.63% over one year, and is currently trading at a 16% discount to the average analyst price target. While some narratives suggest it's undervalued with a fair value of $266.94, others point to its rich P/S ratio (16.9x) compared to industry averages, raising questions about whether its growth can justify the premium.

MAY 14·Investing.com Nigeria

Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.com

Axsome Therapeutics Inc. stock reached an all-time high of $234.57, reflecting a 123.94% increase over the past year and a market capitalization of $12 billion. Despite a significant earnings miss in Q1 2026, with a net loss of $1.26 per share, investor optimism persists. The company's revenue surged 64% over the last twelve months to $708 million, maintaining a gross profit margin of 93%.

MAY 4·Investing.com Canada

Oppenheimer raises Axsome Therapeutics price target on Auvelity sales By Investing.com

Oppenheimer has increased its price target for Axsome Therapeutics (NASDAQ:AXSM) to $280 from $250, maintaining an Outperform rating, following strong first-quarter 2026 Auvelity sales of $153.2 million, which exceeded consensus. The company also revised its Auvelity total peak sales guidance to approximately $8 billion from $4 billion. Despite a recent EPS and revenue miss, analysts from Guggenheim and TD Cowen also raised their price targets, reflecting confidence in Axsome's product performance and strategic expansion, including growing its salesforce for major depressive disorder and an upcoming launch for agitation associated with dementia.

News on $AXSM

All news →